Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adefovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
| ▸ | POLG | P54098 | 1/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.54 |
| ▸ | NSD2 | O96028 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adefovir SCHEMBL29365535 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL28511793 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL28571494 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29115272 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL3639260 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL439995 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL28765885 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL3643715 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29064626 | 0.99 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL439994 | 0.95 | FGFR1 (0.91) | FGFR1SLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23892 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122005580-A | Application of adefovir in preparing medicine for preventing and treating atherosclerosis | 济宁市第一人民医院(济宁市医学科学研究院) | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4444311-B1 | GINSENOSIDES FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTIONS | MENDEL UNIV IN BRNO (CZ) | 2026-05-06 | — | — | EP | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-5763424-A | SEQUESTERING AGENT | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | claimed |
| US-5627165-A | ANTIVIRAL AND ANTILEUKEMIA AGENTS | DRUG INNOVATION & DESIGN, INC. (US) | 1997-05-06 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1996040704-A1 | PYRAZOLE-RELATED DERIVATIVES ENDOWED WITH ANTITUMOR AND ANTIVIRAL ACTIVITIES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM SARC S.C.R.L. (IT) | 1996-12-19 | — | — | WO | claimed |
| EP-0533833-B1 | PHOSPHOROUS PRODUGS | GLAZIER ARNOLD (US) | 1995-12-20 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| EP-0533833-A1 | PHOSPHOROUS PRODRUGS. | GLAZIER ARNOLD (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1991019721-A1 | PHOSPHOROUS PRODUGS | GLAZIER ARNOLD (US) | 1991-12-26 | — | — | WO | claimed |
| WO-1990000555-A1 | LIPID DERIVATIVES OF ANTIVIRAL NUCLEOSIDES, LIPOSOMAL INCORPORATION AND METHOD OF USE | VICAL, INC. (US) | 1990-01-25 | — | — | WO | claimed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | claimed |